{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:11:40Z","timestamp":1779923500688,"version":"3.53.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s12325-024-02996-6","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T09:11:08Z","timestamp":1730193068000},"page":"4669-4682","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Updated Results from the Retrospective CREST Study on the Safety and Effectiveness of 8-Week Glecaprevir\/Pibrentasvir in HCV-Infected Treatment-Na\u00efve Patients with Compensated Cirrhosis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9141-8001","authenticated-orcid":false,"given":"Markus","family":"Cornberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"H\u00fcppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Ahumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Jorquera Plaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Isidro Uriz","family":"Otano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Myles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alnoor","family":"Ramji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Abergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Larrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Persico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Carmiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhi","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bondin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Butrymowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Semizarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana","family":"Sonparote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Llamas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The CREST Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"2996_CR1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","volume":"7","author":"S Blach","year":"2022","unstructured":"Blach S, Terrault NA, Tacke F, et al. Global change in hepatitis\u00a0C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7:396\u2013415.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2996_CR2","unstructured":"World Health Organization (WHO). Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact. 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240027077. Accessed October 2023."},{"key":"2996_CR3","unstructured":"European Association for the Study of the Liver, Clinical Practice Guidelines Panel Chair, EASL Governing Board representative, Panel members. EASL recommendations on treatment of hepatitis\u00a0C: Final update of the series. J Hepatol. 2020;73:1170\u2013218."},{"key":"2996_CR4","unstructured":"AbbVie. Maviret EU Summary of Product Characteristics; 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf. Accessed October 2023."},{"key":"2996_CR5","unstructured":"AbbVie. Mavyret US Package Insert; 2021. https:\/\/www.rxabbvie.com\/pdf\/mavyret_pi.pdf. Accessed October 2023."},{"key":"2996_CR6","unstructured":"AbbVie. Maviret Product Monograph; 2022. https:\/\/www.abbvie.ca\/content\/dam\/abbvie-dotcom\/ca\/en\/documents\/products\/MAVIRET_PM_EN.pdf. Accessed October 2023."},{"issue":"2544\u201353","key":"2996_CR7","volume":"18","author":"E Zuckerman","year":"2020","unstructured":"Zuckerman E, Gutierrez JA, Dylla DE, et al. Eight weeks of treatment with glecaprevir\/pibrentasvir is safe and efficacious in an integrated analysis of treatment-na\u00efve patients with hepatitis\u00a0C virus infection. Clin Gastroenterol Hepatol. 2020;18(2544\u201353):e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2996_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown Jr","year":"2020","unstructured":"Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir\/pibrentasvir for 8\u00a0weeks in treatment-naive patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72:441\u20139.","journal-title":"J Hepatol"},{"key":"2996_CR9","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s12325-020-01301-5","volume":"37","author":"SL Flamm","year":"2020","unstructured":"Flamm SL, Kort J, Marx SE, et al. Effectiveness of 8-week glecaprevir\/pibrentasvir for treatment-naive, compensated cirrhotic patients with chronic hepatitis\u00a0C infection. Adv Ther. 2020;37:2267\u201374.","journal-title":"Adv Ther"},{"key":"2996_CR10","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1007\/s12325-020-01449-0","volume":"37","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Mauss S, Persico M, et al. Real-world clinical practice use of 8-week glecaprevir\/pibrentasvir in treatment-na\u00efve patients with compensated cirrhosis. Adv Ther. 2020;37:4033\u201342.","journal-title":"Adv Ther"},{"key":"2996_CR11","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1111\/liv.14937","volume":"41","author":"H Klinker","year":"2021","unstructured":"Klinker H, Naumann U, Rossle M, et al. Glecaprevir\/pibrentasvir for 8\u00a0weeks in patients with compensated cirrhosis: safety and effectiveness data from the German Hepatitis\u00a0C-Registry. Liver Int. 2021;41:1518\u201322.","journal-title":"Liver Int"},{"key":"2996_CR12","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s40121-021-00455-1","volume":"10","author":"A Aghemo","year":"2021","unstructured":"Aghemo A, Horsmans Y, Bourgeois S, et al. Real-world outcomes in historically underserved patients with chronic hepatitis\u00a0C infection treated with glecaprevir\/pibrentasvir. Infect Dis Ther. 2021;10:2203\u201322.","journal-title":"Infect Dis Ther"},{"key":"2996_CR13","doi-asserted-by":"crossref","first-page":"954A","DOI":"10.1016\/j.jhep.2019.01.015","volume":"70","author":"P Lampertico","year":"2019","unstructured":"Lampertico P, Peck-Radosavljevic M, Bondin M, et al. Addressing barriers to hepatitis\u00a0C virus (HCV) elimination: real-world outcomes in historically underserved patients with chronic HCV infection treated with glecaprevir\/pibrentasvir. Hepatology. 2019;70:954A-A955.","journal-title":"Hepatology"},{"key":"2996_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","volume":"70","author":"R D'Ambrosio","year":"2019","unstructured":"D\u2019Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis\u00a0C. J Hepatol. 2019;70:379\u201387.","journal-title":"J Hepatol"},{"key":"2996_CR15","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/ggi.13919","volume":"20","author":"A Kinoshita","year":"2020","unstructured":"Kinoshita A, Koike K, Mizuno Y, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients with hepatitis\u00a0C virus infection aged \u226575\u00a0years. Geriatr Gerontol Int. 2020;20:578\u201383.","journal-title":"Geriatr Gerontol Int"},{"key":"2996_CR16","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1007\/s12325-022-02158-6","volume":"39","author":"M Cornberg","year":"2022","unstructured":"Cornberg M, Ahumada A, Aghemo A, et al. Safety and effectiveness using 8\u00a0weeks of glecaprevir\/pibrentasvir in HCV-infected treatment-na\u00efve patients with compensated cirrhosis: the CREST Study. Adv Ther. 2022;39:3146\u201358.","journal-title":"Adv Ther"},{"key":"2996_CR17","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"C Clopper","year":"1934","unstructured":"Clopper C, Pearson E. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404\u201313.","journal-title":"Biometrika"},{"key":"2996_CR18","unstructured":"University of Liverpool. HEP drug interactions. 2019. https:\/\/www.hep-druginteractions.org\/checker. Accessed October 2023."},{"key":"2996_CR19","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1111\/liv.14170","volume":"39","author":"M Persico","year":"2019","unstructured":"Persico M, Aglitti A, Milella M, et al. Real-life glecaprevir\/pibrentasvir in a large cohort of patients with hepatitis\u00a0C virus infection: the MISTRAL study. Liver Int. 2019;39:1852\u20139.","journal-title":"Liver Int"},{"key":"2996_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown Jr","year":"2020","unstructured":"Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir\/pibrentasvir for 8\u00a0weeks in treatment-na\u00efve patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72:441\u20139.","journal-title":"J Hepatol"},{"key":"2996_CR21","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s40121-022-00599-8","volume":"11","author":"RS Brown Jr","year":"2022","unstructured":"Brown RS Jr, Collins MA, Strasser SI, et al. Efficacy and safety of 8-or 12\u00a0weeks of glecaprevir\/pibrentasvir in patients with evidence of portal hypertension. Infect Dis Ther. 2022;11:913\u201324.","journal-title":"Infect Dis Ther"},{"key":"2996_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103247","volume":"96","author":"A Amoako","year":"2021","unstructured":"Amoako A, Ortiz-Paredes D, Engler K, Lebouch\u00e9 B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis\u00a0C treatment among priority populations in high income countries: a knowledge synthesis. Int J Drug Policy. 2021;96:103247.","journal-title":"Int J Drug Policy"},{"key":"2996_CR23","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/jvh.12393","volume":"22","author":"AA Artenie","year":"2015","unstructured":"Artenie AA, Jutras-Aswad D, Roy \u00c9, et al. Visits to primary care physicians among persons who inject drugs at high risk of hepatitis\u00a0C virus infection: room for improvement. J Viral Hepat. 2015;22:792\u20139.","journal-title":"J Viral Hepat"},{"key":"2996_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jhep.2019.01.012","volume":"70","author":"T Papaluca","year":"2019","unstructured":"Papaluca T, McDonald L, Craigie A, et al. Outcomes of treatment for hepatitis\u00a0C in prisoners using a nurse-led, statewide model of care. J Hepatol. 2019;70:839\u201346.","journal-title":"J Hepatol"},{"key":"2996_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s40121-021-00410-0","volume":"10","author":"M Andreoni","year":"2021","unstructured":"Andreoni M, Di Perri G, Persico M, et al. Addressing HCV elimination barriers in Italy: healthcare resource utilization and cost impact using 8\u00a0weeks\u2019 glecaprevir\/pibrentasvir therapy. Infect Dis Ther. 2021;10:763\u201374.","journal-title":"Infect Dis Ther"},{"key":"2996_CR26","doi-asserted-by":"publisher","first-page":"23473","DOI":"10.1038\/s41598-021-03006-3","volume":"11","author":"C-F Huang","year":"2021","unstructured":"Huang C-F, Kuo H-T, Chang T-S, et al. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. Sci Rep. 2021;11:23473.","journal-title":"Sci Rep"},{"key":"2996_CR27","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/jvh.13600","volume":"28","author":"E Gane","year":"2021","unstructured":"Gane E, de Ledinghen V, Dylla DE, et al. Positive predictive value of sustained virologic response 4\u00a0weeks posttreatment for achieving sustained virologic response 12\u00a0weeks posttreatment in patients receiving glecaprevir\/pibrentasvir in phase\u00a02 and 3 clinical trials. J Viral Hepat. 2021;28:1635\u201342.","journal-title":"J Viral Hepat"},{"key":"2996_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-12-327","volume":"12","author":"J Brown","year":"2012","unstructured":"Brown J, Demou E, Tristram MA, Gilmour H, Sanati KA, Macdonald EB. Employment status and health: understanding the health of the economically inactive population in Scotland. BMC Public Health. 2012;12:1\u20139.","journal-title":"BMC Public Health"},{"key":"2996_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12939-020-01375-1","volume":"20","author":"SL Lueckmann","year":"2021","unstructured":"Lueckmann SL, Hoebel J, Roick J, et al. Socioeconomic inequalities in primary-care and specialist physician visits: a systematic review. Int J Equity Health. 2021;20:1\u201319.","journal-title":"Int J Equity Health"},{"issue":"3","key":"2996_CR30","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12072-023-10506-z","volume":"17","author":"TS Chang","year":"2023","unstructured":"Chang TS, Huang CF, Kuo HT, et al. Effectiveness and safety of 8-week glecaprevir\/pibrentasvir in HCV treatment-na\u00efve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry. Hepatol Int. 2023;17(3):550\u201361.","journal-title":"Hepatol Int"},{"key":"2996_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06983-y","volume":"22","author":"M Andreoni","year":"2022","unstructured":"Andreoni M, Coppola N, Crax\u00ec A, et al. Meet\u2013test\u2013treat for HCV management: patients\u2019 and clinicians\u2019 preferences in hospital and drug addiction services in Italy. BMC Infect Dis. 2022;22:1\u201314.","journal-title":"BMC Infect Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02996-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02996-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02996-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T08:12:47Z","timestamp":1731139967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02996-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2996"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02996-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Markus Cornberg: Honoraria for lectures and advisory boards for AbbVie, Gilead, GlaxoSmithKline, Janssen-Cilag, SOBI, Novartis, Spring Bank, Roche, Falk, and Merck (MSD); scientific secretary of the German Liver Foundation and member of the coordinating committee of the Federal Ministry of Health \u201cBIS 2030 \u2013 Strategy for the containment of HIV, hepatitis\u00a0B and C and other sexually transmitted infections,\u201d and member of the Scientific Committee and Governing Board of the EASL from 2017\u20132020. Dietrich H\u00fcppe: Speaker for AbbVie. Christoph Sarrazin: Honoraria for consulting\/speaking for AbbVie, Gilead, and Merck Sharp and Dohme. Francisco Jorquera Plaza: Speaker for AbbVie and Gilead; and advisory board participation for Intercept. Zoe Mari\u00f1o: Lecture and consultancy fees from AbbVie and Gilead, research grants from AbbVie and Gilead. Brian Conway: Research and grant support from, and participation in advisory boards: AbbVie, Gilead Sciences, GSK, Indivior, Merck, Moderna, Sanofi Pasteur, and ViiV. Lindsay Myles: Consultant: AbbVie and Gilead Sciences; speaker and participation in advisory boards: AbbVie and Gilead Sciences. Alnoor Ramji: Advisory Committees or Review Panels: AbbVie, Gilead Sciences, Intercept, Janssen, Novo Nordisk, and Pfizer; grant\/research support: AbbVie, Assembly, Galmed, Gilead Sciences, Intercept, Janssen, Merck, Novartis, Novo Nordisk, and Pfizer. Tarik Asselah: Speaker and\/or advisory board member and\/or investigator for AbbVie, Eiger Biopharmaceutical, Gilead, Janssen, Myr Pharmaceutical, Roche, and Merck. Dominique Larrey: Consultancy fees and\/or honoraria from Aegerion, Amryt, and Sanofi. Alessio Aghemo: Grant support by AbbVie and Gilead; Advisory board for Alfasigma, Gilead, Intercept, MSD, Mylan, and Sobi. Massimo Andreoni: Payment or honoraria for lectures, presentations, or educational events from AbbVie, Gilead Sciences, Janssen Tibotec, ViiV healthcare. Support for attending meetings and\/or travel from AbbVie, Gilead Sciences, ViiV healthcare. Advisory Board for AstraZeneca, Gilead Sciences, Moderna, Pfizer. Antonio Gasbarrini: Consultant for AbbVie, Actial, Alfasigma, Eisai, Gilead, MSD, Sandoz, Sanofi, and Takeda. Pietro Lampertico: Speaker bureau and\/or advisory board for Bristol Myers, Squibb, Roche, Gilead, GlaxoSmithKline, MSD, AbbVie, Arrowhead, Alnylam, Eiger, Myr Pharma, and Janssen. Marcello Persico: Consultant and speaker for AbbVie, Gilead, and MSD. Michal Carmiel: Honorarium fees for consulting and\/or participating in speaker bureaus from AbbVie. Abhi Bhagat, Mark Bondin, Isabel Butrymowicz, Yanna Song, Dimitri Semizarov, Sadhana Sonparote, Cynthia Llamas: Employees of AbbVie Inc. USA and may hold stock\/options. Armand Abergel, Adriana Ahumada, Gabriel Chodick, Juan Isidro Uriz Otano, Erica Villa, and Clara Weil: Nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study protocol was conducted in accordance with the Declaration of Helsinki. Each participating clinician signed an agreement attesting to compliance with all rules and regulations regarding the disclosure of patient information. Data were collected through a retrospective review of existing data recorded by the investigator in such a manner that the identity of the patients could not be readily ascertained directly or through identifiers linked to the patients. The investigator did not contact the patients, and the investigator did not re-identify patients. The study was granted an exemption from obtaining informed patient consent and approved by the Veritas Independent Review Board and the Saskatchewan Health Authority and the Ottawa Hospital Research Institute and the Hamilton Integrated Research Ethics Boards (HiREB) (Canada), the Institutional Review Board of Maccabi Healthcare Services (Israel), the Department of Medicines for Human Use of the Spanish Agency for Medicines and Health Products (AEMPS) and the Research Ethics Committee from the Medicines Gregorio Mara\u00f1\u00f3n General University Hospital (Spain), and the Ethics Committee of the Medical Association of Westphalia-Lippe and the Westphalian Wilhelms University Board (Germany). The study was approved by each of the institutional ethics committees for the sites in Italy. The study protocol was registered in the Health Data Hub and was conducted in accordance with the CNIL methodology of reference MR-004 (France).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}